Pro Medicus (ASX: PME): A Phenomenal Surge of 784% in ASX 200 Healthcare in last 5 years

2 min read | November 27, 2023 01:35 AM AEDT | By Team Kalkine Media

Google News:

Pro Medicus (ASX: PME): A Phenomenal Surge of 784% in ASX 200 Healthcare in last 5 years — Image source: shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

e Pro Medicus Ltd (ASX:PME) healthcare share has yet again marked a surge, currently trading at AU$89.21 from AU$88.59 at yesterday's close. With a staggering 784% rise in five years and a recent surge of 64% in 2023, investors are curious about the sustainability of this remarkable growth trajectory.

Analyst's Positive Outlook for Pro Medicus

Michelle Lopez, head of Australian equities at Pie Funds Management, expresses strong optimism about Pro Medicus' future growth potential. Labeling it a "high-quality, high-growth, long-term compounder," Lopez forecasts a substantial 30% annual growth over the next three years, citing a robust earnings trajectory.

FY 2023 Financial Performance

Pro Medicus demonstrated robust financial growth in FY 2023. The company's revenue soared by 33.6% to AU$125 million, accompanied by a 36.5% surge in net profit after tax (NPAT) to AU$61 million. The full-year dividend saw a significant increase of 36.4% to 30 cents per share, reflecting positive financial health.

Future Growth Drivers: AI Integration & Technological Evolution

The company's investment in AI integration remains pivotal for future growth. Pro Medicus, keen on technological evolution, recruited dedicated personnel for AI-related endeavors in FY 2023. CEO Sam Hupert emphasized the role of cloud-based systems and modular approaches, providing scalability and flexibility for future innovations.

Conclusion

Pro Medicus' remarkable growth in recent years and positive projections from analysts underpin the company's strong market position. With continued focus on technological advancements and AI integration, Pro Medicus seems poised for sustained growth, resonating well with shareholders and industry analysts.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.